New Partnerships & Brand Loyalty - Research Report on Acura Pharmaceuticals, Élan Corp, Hospira, Alkermes and Valeant

 New Partnerships & Brand Loyalty - Research Report on Acura Pharmaceuticals,
                   Élan Corp, Hospira, Alkermes and Valeant

PR Newswire

NEW YORK, March 8, 2013

NEW YORK, March 8, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Acura
Pharmaceuticals, Inc. (NASDAQ: ACUR), Élan Corporation, Plc (NYSE: ELN),
Hospira, Inc. (NYSE: HSP), Alkermes Plc. (NASDAQ: ALKS) and Valeant
Pharmaceuticals Intl Inc. (NYSE: VRX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Acura Pharmaceuticals, Inc. Research Report

Acura Pharmaceuticals enters the chain drug store market via its new next
generation pseudoephedrine with abuse deterrent technology.
Nexafed[pseudoephedrine hydrochloride (HCI)] - a 30 mg immediate-release
pseudoephedrine product that combines effective nasal-congestion relief with a
unique technology that disrupts the conversion of pseudoephedrine into the
dangerous drug, methamphetamine (meth) - will now be stocked by KERR DRUG
chain of stores. "We are extremely pleased with KERR DRUG's decision to join
the fight against methamphetamine abuse by stocking Nexafed," said Robert B.
Jones, president and chief executive officer of Acura Pharmaceuticals. "We
anticipated early interest in Nexafed from independent pharmacies but it is
rewarding that forward-looking drug chains like KERR DRUG are stepping up to
make a difference in the communities in which they operate." The Full Research
Report on Acura Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investors-alliance.com/r/full_research_report/b2f1_ACUR]

Élan Corporation, PLC. Research Report

A unique cash flow dividend policy has been approved by the Board of Élan
Corporation that'll enable its shareholders to benefit directly from the long
term cash flow generated by Tysabri. The dividend program will be directly
linked to Tysabri market performance calculated as a percentage of the Tysabri
royalty paid to Élan from Biogen Idec as a result of the recently announced
Tysabri restructuring. The initial percentage to be paid out directly to
shareholders is 20 % of those royalties. The uncapped dividend cash payments
give shareholders the right to enjoy unlimited participation in the upside
from the Tysabri sales increase. The payments will be done in twice-yearly
installments, with the first payment expected in the fourth quarter of 2013.
The Full Research Report on Élan Corporation, PLC. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.investors-alliance.com/r/full_research_report/294e_ELN]

Hospira, Inc. Research Report

Royce R. Bedward joins Hospira as its new corporate vice president, general
counsel and secretary effective immediately. "Royce is an accomplished lawyer
and integrity-driven business leader with more than 10 years of experience in
the healthcare field and a proven track record of success at Hospira," said
Mr. F. Michael Ball, Hospira CEO. "We look forward to Royce's many additional
contributions, while thanking Brian for his continued service and counsel.
Working together, I'm confident that their strong leadership abilities will
help position Hospira for a stronger future of sustainable, long-term growth
and drive greater value for our stakeholders. "Mr. Bedward will oversee the
company's legal department, including litigation, benefits, labor and
employment, intellectual property, governance, securities and transactional
matters. Hospira, Inc. is the world's leading provider of injectable drugs and
infusion technologies. Through its broad, integrated portfolio, Hospira is
uniquely positioned to Advance Wellness by improving patient and caregiver
safety while reducing healthcare costs. The company is headquartered in Lake
Forest, Ill., and has approximately 16,000 employees. The full Research Report
on Hospira, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/44b1_HSP]

Alkermes Plc. Research Report

It was a good third quarter for Alkermes as non-GAAP diluted EPS grew to $0.34
from $0.10, prompting improved financial expectations for its fiscal year
2013. "With results now spanning an entire year, the power of Alkermes Plc is
becoming evident. Our strong financial performance was driven by our five key
commercial products, which grew 33% year-over-year," commented James Frates,
Chief Financial Officer of Alkermes. "Today, we are again improving our
financial expectations for fiscal 2013, based on our robust operational
performance across the business. We now expect Alkermes to generate between
$135 million and $155 million in non-GAAP net income this fiscal year."
Manufacturing and royalty revenues from the company's long-acting atypical
antipsychotic franchise RISPERDAL, CONSTA, and INVEGA SUSTENNA/XEPLION amount
to $52.5 million. Net sales, and royalty and manufacturing of its other
products also contributed to the increase in revenue for the company. The Full
Research Report on Alkermes Plc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/2f8e_ALKS]

Valeant Pharmaceuticals Intl Inc. Research Report

It was a healthy 2012 Q4 for Valeant Pharmaceuticals as the company posted
good figures, thanks to organic growth. For Q4, total revenue amounted to $986
million, a 43% increase over the prior year with same store sales up by 7%.
For the full year, the company enjoys a 44% increase in total revenue
amounting to $3.55 billion versus 2011's $2.46 billion. The company's U.S.
Dermatology business has shown solid growth, thanks to the sales performance
of Zovirax, Retin-A Micro, Acanya, Carac and CeraVe. Valeant's other portfolio
also delivered positive results, reflecting the diminishing year over year
negative impact from generic competitors of Wellburtin XL, Ultram and Cardizem
CD. The Full Research Report on Valeant Pharmaceuticals Intl Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/8d49_VRX]

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-(408)-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.